This was the stock's fourth consecutive day of gains.

Rising prevalence of cancer, breakthrough research in epigenetic drugs, and increased funding in innovative technologies propel market growth at a CAGR of 15.3%Pune, Jan. 09, 2025 (GLOBE NEWSWIRE) -- ...

This strategy can endure through a rough patch. Our research team assigns Silver ratings to strategies that they have a high conviction will outperform the relevant index, or most peers, over a ...